HCM
REGN icon

Hayman Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hayman Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,506
Closed -$1.28M – 31
2015
Q2 		$1.28M Buy
+2,506
New +$1.22M 0.15% 38

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Hayman Capital Management's REGN Position: Q3 2015 in Review

Hayman Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 2,506 shares — an estimated $1.28M sold.

Hayman Capital Management first reported a position in REGN in Q2 2015 and held it in 1 quarter. The position peaked at $1.28M in Q2 2015. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Hayman Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Hayman Capital Management sold 2,506 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $1.28M.
  • Hayman Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Hayman Capital Management's Regeneron Pharmaceuticals position peaked at $1.28M in Q2 2015.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Hayman Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.